Rankings
▼
Calendar
REGN Q1 2016 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q1 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.2B
Gross Profit
$1.1B
90.7% margin
Operating Income
$329M
27.4% margin
Net Income
$166M
13.8% margin
EPS (Diluted)
$1.59
Cash Flow
Operating Cash Flow
$45M
Free Cash Flow
-$59M
Stock-Based Comp.
$142M
Balance Sheet
Total Assets
$5.9B
Total Liabilities
$2.1B
Stockholders' Equity
$3.8B
Cash & Equivalents
$604M
Revenue Segments
Antibody Collaboration
$170M
78%
Immuno-oncology Agreement
$49M
22%
← FY 2016
All Quarters
Q2 2016 →
